Dublin, Aug. 08, 2022 (GLOBE NEWSWIRE) -- The "TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global TIM-3 ...
New York, July 21, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight ...
DUBLIN--(BUSINESS WIRE)--The "TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global TIM-3 inhibitor market is ...
Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II clinical trial. Safety of AK117 ...
CXCR4 overexpression: An indicator of poor survival and predictor of response to immunotherapy in patients with metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results